The third stage of trials of another vaccine against coronavirus begins in the USA

“Novavax ... today announced the start of a major third phase of trials in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of its candidate COVID-19 vaccine, NVX-CoV2373,” the press release said.

According to the company, initial studies showed an active immune response, the production of neutralizing antibodies and a good tolerance of the vaccine.

The third phase of research in the United States and Mexico will involve up to 30 thousand volunteers aged 18 and over, who will be injected with a vaccine and placebo.

At the end of September, Novavax began the third phase of trials of the COVID-19 vaccine in the UK.